SMAD3 often acts as a mediator of TGF-β superfamily that modulates signaling and has been implicated as a driving event in cancer metastasis.81 The acetylation of SMAD3 at K20 and K117 by KAT6A promotes its association with oncogenic chromatin modifier TRIM24 and disrupts its interaction with the tumor suppressor TRIM33, enhancing the transcription of immune response-related cytokines. This evidence concerns the gene SMAD3 and cancer.